SHAPING THE FUTURE OF
n (Life Sciences & Allied Applications / Biology) the mimicking of life using imitation biological systems
Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.1
Veryan benefits from a highly experienced Board of Directors and the Company’s management team has built an outstanding development group, supported by a world class Scientific Advisory Board. The Company’s head office is in Horsham, West Sussex, UK, the research and development facility is in Galway, Ireland and the US clinical team is based in Wilmington, Delaware.
Veryan shareholders include: Imperial Innovations Group plc; Seroba Life Sciences; Oxford Capital Partners; Seven Mile Capital Partners; National Endowment for Science and Arts (NESTA); management and founders.
Veryan’s Quality Management System is certified in compliance with I.S. EN ISO 13485:2012 (Click here to view)
1. Caro, C. G. Discovery of the role of wall shear in atherosclerosis. Arterioscler Thromb Vasc Biol 29, 158–61 (2009).